Search

Displaying results 1521 - 1530 of 5419 in total
  1. Drug

    Bacillus calmette-guerin substrain tice live antigen

    go.drugbank.com/drugs/DB10343
    ApprovedInvestigational

    Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use

  2. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

  3. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...

    Mixtures: Nu-chlorax Capsules USP
  4. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L42305] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended faricimab be granted marketing authorization for the treatment of neovascular age-related macular degeneration … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.

  5. Drug

    OSI-7904L

    go.drugbank.com/drugs/DB05457
    Investigational

    OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). … Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.

  6. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  7. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.

  8. Drug

    Diamorphine

    go.drugbank.com/drugs/DB01452
    ApprovedIllicit

    Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.

  9. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma

  10. Drug

    Parethoxycaine

    go.drugbank.com/drugs/DB19380
    ApprovedWithdrawn

    Parethoxycaine is a local anesthetic that was previously approved in the US.